John N. Nunnelly Sells 2,383 Shares of National Research Co. (NRCIA) Stock

National Research Co. (NASDAQ:NRCIA) Director John N. Nunnelly sold 2,383 shares of the company’s stock in a transaction dated Friday, March 16th. The stock was sold at an average price of $31.74, for a total value of $75,636.42. Following the completion of the transaction, the director now directly owns 31,842 shares of the company’s stock, valued at approximately $1,010,665.08. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

National Research Co. (NASDAQ NRCIA) opened at $30.80 on Friday. National Research Co. has a fifty-two week low of $18.81 and a fifty-two week high of $41.99. The stock has a market capitalization of $763.49, a PE ratio of 59.23 and a beta of 1.75.

The business also recently declared a quarterly dividend, which will be paid on Friday, April 13th. Stockholders of record on Friday, March 30th will be paid a $0.10 dividend. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $0.40 annualized dividend and a dividend yield of 1.30%. National Research’s payout ratio is 76.92%.

NRCIA has been the subject of a number of recent research reports. Zacks Investment Research raised National Research from a “sell” rating to a “hold” rating in a report on Tuesday, February 6th. BidaskClub cut National Research from a “buy” rating to a “hold” rating in a report on Friday, January 19th.

Several hedge funds have recently modified their holdings of the company. Dimensional Fund Advisors LP increased its stake in shares of National Research by 1.3% in the third quarter. Dimensional Fund Advisors LP now owns 605,856 shares of the business services provider’s stock valued at $22,841,000 after buying an additional 7,666 shares during the period. BlackRock Inc. increased its stake in shares of National Research by 0.6% in the fourth quarter. BlackRock Inc. now owns 476,279 shares of the business services provider’s stock valued at $17,765,000 after buying an additional 2,620 shares during the period. Conestoga Capital Advisors LLC increased its stake in shares of National Research by 7.5% in the fourth quarter. Conestoga Capital Advisors LLC now owns 453,436 shares of the business services provider’s stock valued at $16,913,000 after buying an additional 31,505 shares during the period. Renaissance Technologies LLC increased its stake in shares of National Research by 27.1% in the fourth quarter. Renaissance Technologies LLC now owns 289,900 shares of the business services provider’s stock valued at $10,813,000 after buying an additional 61,900 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of National Research by 2.8% in the second quarter. Vanguard Group Inc. now owns 260,010 shares of the business services provider’s stock valued at $6,994,000 after buying an additional 7,177 shares during the period. 33.66% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This report was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3293554/john-n-nunnelly-sells-2383-shares-of-national-research-co-nrcia-stock.html.

National Research Company Profile

National Research Corporation, doing business as NRC Health, is a provider of analytics and insights for healthcare providers, payers and other healthcare organizations. The Company operates through six segments: Experience, The Governance Institute, Market Insights, Transparency, National Research Corporation Canada and Connect.

Insider Buying and Selling by Quarter for National Research (NASDAQ:NRCIA)

Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Ryder  PT Lowered to $76.00
Ryder PT Lowered to $76.00
The Hackett Group  Stock Rating Lowered by Zacks Investment Research
The Hackett Group Stock Rating Lowered by Zacks Investment Research
IMI  Stock Rating Lowered by Zacks Investment Research
IMI Stock Rating Lowered by Zacks Investment Research
Zacks Investment Research Upgrades Healthcare Trust Of America  to Hold
Zacks Investment Research Upgrades Healthcare Trust Of America to Hold
Croda International  Rating Reiterated by Liberum Capital
Croda International Rating Reiterated by Liberum Capital
Heidrick & Struggles  Expected to Post Q2 2018 Earnings of $0.43 Per Share
Heidrick & Struggles Expected to Post Q2 2018 Earnings of $0.43 Per Share


© 2006-2018 Ticker Report. Google+.